Emgality^®: a migraine treatment that can fit into your patient’s life¹

2022 Formulary Update

Emgality remains Preferred Brand Tier on CVS National Commercial Template Formularies and Aimovig^® is no longer on the Preferred Brand Tier.^a

^aFor the preventive treatment of migraine Emgality and Ajovy^® remain in the Preferred Brand Tier across CVS Caremark Value Formulary, Advanced Control Formulary, CVS Caremark Performance Drug List - Standard Control, and CVS Caremark Performance Drug List - Standard Opt Out Commercial Formularies. Aimovig^® is excluded, effective 1/1/2022, on all previously listed formularies except the CVS Caremark Performance Drug List - Standard Opt Out formulary.

^*Based on total prescriptions of subcutaneous calcitonin gene-related peptide (CGRP) antibody injections written after 12/31/2021. Data as of 7/1/2022.

Source: IQVIA database as of 7/1/2022 and is subject to change without notice.

^†Best-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.⁴ Does not take into consideration any restrictions set forth by individual plans. Data as of 7/1/2022.

Source: Managed Markets Insight & Technology (MMIT), LLC as of 7/1/2022 and is subject to change without notice. Please contact the plan or state for the most current information. “Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employers and employer groups may also offer additional benefit designs, which may be different than described.

Have questions about Emgality?

Call us at 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumabgnlm or to any of the excipients.

For the preventive treatment of migraine in adults¹

Watch how to use the Emgality Pen or Prefilled Syringe

Request your Emgality Loading Dose Kit samples, delivered by your Lilly Sales Representative^a

The Loading Dose Kit (sample) lets you provide patients living with migraine a chance to try out administering the first monthly dose of Emgality (2 injections of 120 mg each), right in your office. After that, patients can inject 1 dose, or injection, on their own each month. Loading Dose Kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.

To request your loading dose kit samples, use the link below to complete and submit your request electronically. Your Rep will deliver your samples directly to your office.

Sample/Sales Representative Request Form

^aSamples are not available for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

The questionnaire is an impact assessment that helps you uncover the burden migraine is placing on your patients’ lives. This understanding can assist you in determining a treatment plan that may be right for your patients.

Learn more about a treatment that can help patients like Jessica

^cGovernmental beneficiaries excluded. Terms and Conditions apply.

These resources are available for your practice

Dosing and Prescribing Comparison by Indication